Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Clinical trial NCT06393374 · RECRUITING

Trial details

NCT number: NCT06393374
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Triple-Negative Breast Cancer

Start date: 2024-06-24
Primary completion: 2030-12-16
Enrollment: 1530

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.